AstraZeneca Posts Stronger-Than-Expected Q1 Earnings on Cancer Drug Sales
AstraZeneca reported stronger-than-expected profit and revenue for the first quarter, driven by a 16% surge in oncology revenue. The growth was fueled by double-digit gains across multiple cancer treatments. The company's performance exceeded analyst forecasts, highlighting the strength of its oncology portfolio.
Key facts
- AstraZeneca posted stronger-than-expected profit and revenue in Q1.
- Oncology revenue climbed 16% in the quarter.
- Growth was driven by double-digit gains across multiple cancer treatments.
- The results exceeded analyst expectations.
Entities
Institutions
- AstraZeneca
Sources
- Quartz —